Sex-Related Differences in the Severity of Neonatal Opioid Withdrawal Syndrome: A Single-Center, Retrospective Cohort Study

Victoria A Anderson; Saminathan Anbalagan; Michael T Favara; Daniela Stark; David Carola; Kolawole O Solarin; Susan Adeniyi-Jones; Zubair H Aghai

doi:10.1055/s-0044-1788717

Sex-Related Differences in the Severity of Neonatal Opioid Withdrawal Syndrome: A Single-Center, Retrospective Cohort Study

Am J Perinatol. 2024 Jul 29. doi: 10.1055/s-0044-1788717. Online ahead of print.

Authors

Victoria A Anderson¹, Saminathan Anbalagan^{2

3}, Michael T Favara⁴, Daniela Stark⁵, David Carola², Kolawole O Solarin², Susan Adeniyi-Jones², Zubair H Aghai²

Affiliations

¹ Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
² Department of Pediatrics/Neonatology, Thomas Jefferson University/Nemours, Philadelphia, Pennsylvania.
³ Department of Pediatrics/Neonatology, University of South Alabama, Mobile, Alabama.
⁴ Department of Pediatrics/Neonatology, ChristianaCare Hospital, Newark, Delaware.
⁵ Department of Pediatrics, NYU Grossman School of Medicine, New York, New York.

PMID: 39074806
DOI: 10.1055/s-0044-1788717

Abstract

Objective: Factors associated with the development and expression of Neonatal Opioid Withdrawal Syndrome (NOWS) are poorly understood. There are conflicting data on the role of infant sex in NOWS. Some studies have suggested that infant sex predicts NOWS severity and adverse outcomes, with male infants being more vulnerable. This study aimed to analyze if infant sex is associated with the severity of NOWS among those who require pharmacologic treatment.

Study design: This is a retrospective cohort study of term and late-preterm infants (≥35 weeks gestation) exposed to in utero opioids, born between September 2006 and August 2022, and required pharmacologic treatment for NOWS. Maternal and infant demographics were collected. Indicators of the severity of NOWS (duration of medical treatment (DOT), duration of hospitalization, maximum dose of opioid treatment, and use of secondary medications) were compared between male and female infants. Standard statistical tests and regression analysis were used to establish the differences in outcomes after accounting for confounders and baseline differences.

Results: Out of the 1,074 infants included in the study, 47.9% were female, and 52.1% were male. There was no significant difference in demographic and baseline clinical characteristics between groups except for anthropometry (birth weight, head circumference, and length) and Apgar score at 5 minutes. The median DOT (25 days [14, 39] vs. 23 days [13, 39], p = 0.57), length of hospital stay (31.5 days [20, 44] vs. 28 days [20, 44], p = 0.35), treatment with phenobarbital (24.7 vs. 26.3%, p = 0.56), and clonidine (3.9 vs. 3.8%, p = 0.9) were similar in both groups. The differences remained nonsignificant after adjusting for birth anthropometric measurements, gestational age, 5-minute Apgar score, small for gestational age status, and maternal exposure to benzodiazepines.

Conclusion: In this cohort of neonates, sex-related differences were not identified to influence the severity of NOWS among those who required pharmacological treatment.

Key points: · Vulnerability to NOWS is multifactorial.. · The role of infant sex in the severity of NOWS is not concrete.. · We noted that sex did not impact NOWS severity in those treated..